I don't really care about estimates. I'll reserve

I don't really care about estimates. I'll reserve judgement until I see actual revenue reports. If it's low and doesn't appear to have much promise, then I'll adjust my expectations accordingly. I don't doubt that it will take time for Lympro to gain traction and I expect that revenue will be lower at the beginning and increase over time. But, I'm certainly not going to claim it's worthless or dead until I have more evidence to that effect.